Hormonal Contraception on HIV Acquisition and Transmission
Study Description
“Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk”
This is a prospective cohort study focusing on HIV negative women. The investigators want to learn how the following types of contraceptive methods: Depot medroxyprogesterone acetate (DMPA), Etonogestrel impant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD) and the ParaGardAR T 380A Intrauterine Copper Contraceptive impacts the vaginal immune environment.
Location
Methods
Pharmaceutical medication involved
Patients and healthy individuals accepted
Drug - Depot medroxyprogesterone acetate (DMPA)
DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
Device - Etonogestrel implant (Eng-Implant)
A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
Device - Levonorgestrel intrauterine device (Lng-IUD)
A standard Mirena IUD will be placed at study week 3 by a trained clinician.
Device - ParaGard® T 380A Intrauterine Copper Contraceptive
A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
Additional Information
Official Study Title
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
Clinical Trial ID
NCT02357368
ParticipAid ID
QbYQOb
